# US 7,410,634 B2 · Tissue metabolic stress monitoring > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,410,634 B2 - Document ID: US7410634B2 - Status: Granted - Kind: B2 - Application number: 11/250,372 - Filed: 2005-10-17 - Published: 2007-04-19 - Granted: 2008-08-12 - Earliest claimed: 2005-10-17 - Assignees: Rockland Technimed Ltd. - Inventors: Pradeep M. Gupte; Robert Louis Delapaz - Web page: https://patentgrep.com/patent/US7410634B2 ## CPC - A61K 49/08: characterised by the carrier - A61K 49/1806: {Suspensions, emulsions, colloids, dispersions} - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Various pathophysiological states are determined by evaluating the rate of 17O-containing water production oxygen using proton MRI. The method can be used to identify viable but threatened myocardium, injured by viable muscle, penumbra tissue in a stroke patient, and the like. ## Claims ### Claim 1 A method of differentiating zones in ischemic tissue by measuring an oxygen extraction fraction in the ischemic tissue by means of a proton magnetic resonance imaging system, the method comprising: administering an effective imaging amount of a diagnostic imaging agent, the diagnostic imaging agent comprising 17O2 and a biologically acceptable carrier, wherein said diagnostic imaging agent has an ionic composition essentially equal to that of blood and an average particle size of less than about 0.6 microns; and determining a risk of tissue damage by comparing a first oxygen extraction fraction of a first tissue zone in the ischemic tissue to a second oxygen extraction fraction of a second tissue zone in the ischemic tissue using the proton magnetic resonance imaging system. ### Claim 2 (depends on 1) The method of claim 1 in which the biologically acceptable carrier comprises blood. ### Claim 3 (depends on 2) The method of claim 2 in which the diagnostic imaging agent further comprises an emulsifying agent. ### Claim 4 (depends on 3) The method of claim 3 in which the first oxygen extraction fraction of the first tissue zone is quantified relative to the second oxygen extraction fraction of the second tissue zone. ### Claim 5 (depends on 1) The method of claim 1 in which the diagnostic imaging agent further comprises an emulsifying agent. ### Claim 6 (depends on 5) The method of claim 5 in which the first oxygen extraction fraction of the first tissue zone is quantified relative to the second oxygen extraction fraction of the second tissue zone. ### Claim 7 (depends on 1) The method of claim 1 in which the first oxygen extraction fraction of the first tissue zone is quantified relative to the second oxygen extraction fraction of the second tissue zone, one of the first and second tissue zones being normal tissue. ### Claim 8 A method of determining penumbra brain tissue in a stroke patient by measuring an oxygen extraction fraction in the brain by means of a proton magnetic resonance imaging system, the method comprising: administering an effective imaging amount of a diagnostic imaging agent, the diagnostic imaging agent comprising a complex of 17O2 and a biologically acceptable liquid carrier, wherein said complex has an ionic composition essentially equal to that of blood and an average particle size of less than about 0.6 microns; and identifying tissue under oxidative stress, said identifying comprising comparing an oxygen extraction fraction from a first tissue zone in the penumbra to an oxygen extraction fraction of a second tissue zone in the penumbra using a proton magnetic resonance imaging system. ### Claim 9 (depends on 8) The method of claim 8 in which the biologically acceptable liquid carrier comprises blood. ### Claim 10 (depends on 9) The method of claim 9 in which the diagnostic imaging agent further comprises an emulsifying agent. ### Claim 11 (depends on 10) The method of claim 10 in which the first oxygen extraction fraction of the first tissue zone is quantified relative to the second oxygen extraction fraction of the second tissue zone. ### Claim 12 (depends on 8) The method of claim 8 in which the diagnostic imaging agent further comprises an emulsifying agent. ### Claim 13 (depends on 12) The method of claim 12 in which the first oxygen extraction fraction of the first tissue zone is quantified relative to the second oxygen extraction fraction of the second tissue zone. ### Claim 14 (depends on 8) The method of claim 8 in which the first oxygen extraction fraction of the first tissue zone is quantified relative to the second oxygen extraction fraction of the second tissue zone. ### Claim 15 (depends on 8) The method of claim 8 further comprising: comparing the oxygen extraction fraction in a third tissue zone in normal brain tissue to the oxygen extraction fraction in the first tissue zone and the second tissue zone by means of the proton magnetic resonance imaging system; and quantifying the oxygen extraction fraction of the third tissue zone relative to the oxygen extraction fraction of the first tissue zone and the second tissue zone. ### Claim 16 (depends on 1) The method of claim 1 further comprising: comparing the oxygen extraction fraction in a third tissue zone in normal tissue to the oxygen extraction fraction in the first tissue zone and the second tissue zone by means of the proton magnetic resonance imaging system; and quantifying the oxygen extraction fraction of the third zone relative to the oxygen extraction fraction of the first zone and the second zone.